000131410 001__ 131410
000131410 005__ 20240731103339.0
000131410 0247_ $$2doi$$a10.2217/fca-2023-0016
000131410 0248_ $$2sideral$$a136426
000131410 037__ $$aART-2023-136426
000131410 041__ $$aeng
000131410 100__ $$aMontero-Pérez-Barquero, Manuel
000131410 245__ $$aProjected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice
000131410 260__ $$c2023
000131410 5203_ $$aAim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure (HF) with reduced ejection fraction in clinical practice in Spain. Materials & methods: This multicenter cohort study included subjects aged 50 years or older consecutively hospitalized for HF in internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were estimated based on results from the DAPA-HF trial. Results: A total of 1595 patients were enrolled, of whom 1199 (75.2%) were eligible for dapagliflozin. Within 1 year after discharge, 21.6% of patients eligible for dapagliflozin were rehospitalized for HF and 20.5% died. Full implementation of dapagliflozin led to an absolute risk reduction of 3.5% for mortality (number needed to treat = 28) and 6.5% (number needed to treat = 15) for HF readmission. Conclusion: Treatment with dapagliflozin in clinical practice may markedly reduce mortality and readmissions for HF.
000131410 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000131410 592__ $$a0.412$$b2023
000131410 593__ $$aCardiology and Cardiovascular Medicine$$c2023$$dQ3
000131410 593__ $$aMolecular Medicine$$c2023$$dQ4
000131410 594__ $$a2.8$$b2023
000131410 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131410 700__ $$aEscobar-Cervantes, Carlos
000131410 700__ $$aArévalo-Lorido, José Carlos
000131410 700__ $$aConde-Martel, Alicia
000131410 700__ $$aSalamanca-Bautista, Prado
000131410 700__ $$aManzano-Espinosa, Luis
000131410 700__ $$aFormiga, Francesc
000131410 700__ $$0(orcid)0000-0002-3132-2171$$aDíez-Manglano, Jesús$$uUniversidad de Zaragoza
000131410 700__ $$aCepeda, José María
000131410 700__ $$aGonzález-Franco, Alvaro
000131410 700__ $$aCasado-Cerrada, Jesús
000131410 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000131410 773__ $$g19, 6 (2023), 343-351$$pFuture cardiol.$$tFuture cardiology$$x1479-6678
000131410 8564_ $$s197527$$uhttps://zaguan.unizar.es/record/131410/files/texto_completo.pdf$$yVersión publicada
000131410 8564_ $$s5954216$$uhttps://zaguan.unizar.es/record/131410/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131410 909CO $$ooai:zaguan.unizar.es:131410$$particulos$$pdriver
000131410 951__ $$a2024-07-31-09:49:17
000131410 980__ $$aARTICLE